Next Article in Journal
Synthesis of a 1-Aryl-2,2-chlorosilyl(phospha)silene Coordinated by an N-Heterocyclic Carbene
Next Article in Special Issue
Optimized and Automated Radiosynthesis of [18F]DHMT for Translational Imaging of Reactive Oxygen Species with Positron Emission Tomography
Previous Article in Journal
Neurodegenerative Diseases: Might Citrus Flavonoids Play a Protective Role?
Previous Article in Special Issue
Molecular-Based Fluorescent Nanoparticles Built from Dedicated Dipolar Thienothiophene Dyes as Ultra-Bright Green to NIR Nanoemitters
Article Menu
Issue 10 (October) cover image

Export Article

Open AccessArticle
Molecules 2016, 21(10), 1308; doi:10.3390/molecules21101308

Re-188 Enhances the Inhibitory Effect of Bevacizumab in Non-Small-Cell Lung Cancer

1,2,†
,
3,†
,
1,2
,
1,2
,
1,2
,
1,2
,
4
,
1,2
and
1,2,*
1
Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China
2
Shanghai Institute of Medical Imaging, Shanghai 200032, China
3
Departments of Respiratory Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China
4
Institute of Applied Physics, Chinese Academy of Sciences, Shanghai 200032, China
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Academic Editor: Zhen Cheng
Received: 18 July 2016 / Revised: 24 September 2016 / Accepted: 25 September 2016 / Published: 30 September 2016
(This article belongs to the Special Issue Molecular Imaging Probes)
View Full-Text   |   Download PDF [10698 KB, uploaded 30 September 2016]   |  

Abstract

The malignant behaviors of solid tumors such as growth, infiltration and metastasis are mainly nourished by tumor neovascularization. Thus, anti-angiogenic therapy is key to controlling tumor progression. Bevacizumab, a humanized anti-vascular endothelial growth factor (VEGF) antibody, plus chemotherapy or biological therapy can prolong survival for cancer patients, but treatment-related mortality is a concern. To improve inhibitory effect and decrease side-effects on non-small-cell lung cancer (NSCLC), we used Re-188, which is a β emitting radionuclide, directly labeled with bevacizumab for radioimmunotherapy in a human A549 tumor model. Cytotoxic assay data showed that, after 188ReO4 or 188Re-bevacizumab at different concentration for 4 and 24 h, a time- and radioactivity does-dependent reduction in cell viability occurred. Also, an apoptosis assay conformed great apoptosis in the 188Re-bevacizumab group compared with controls and other treatment groups. In vivo, tumor volumes in the 188Re-bevacizumab (11.1 MBq/mice) group were not reduced but growth was delayed compared with other groups. Thus, 188Re-bevacizumab enhanced the therapeutic effect of bevacizumab, suggesting a potential therapeutic strategy for NSCLC treatment. View Full-Text
Keywords: bevacizumab; non-small cell lung cancer; radioimmunotherapy; Re-188; Tc-99m bevacizumab; non-small cell lung cancer; radioimmunotherapy; Re-188; Tc-99m
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Xiao, J.; Xu, X.; Li, X.; Li, Y.; Liu, G.; Tan, H.; Shen, H.; Shi, H.; Cheng, D. Re-188 Enhances the Inhibitory Effect of Bevacizumab in Non-Small-Cell Lung Cancer. Molecules 2016, 21, 1308.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]

Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top